Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ResMed (RMD) is back in focus after reporting higher sales and net income for ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ResMed (NYSE:RMD) is seeing growing use of wearable devices for sleep apnea pre ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Sydney: Sleep-breathing device maker ResMed plans to take global a doctor ‍education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, ⁠calling ...

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business model. I rate RMD a strong sell due to the imminent threat from Apnimed's ...

ResMed Inc. (NYSE:RMD) presented its second-quarter fiscal year 2026 results on January 29, 2026, showcasing strong financial performance with revenue growth of 9% at constant currency. Despite ...

Resmed posts double-digit revenue and profit growth in Q2 FY26, declares dividend, and outlines plans for innovation. The Resmed CDI (ASX: RMD) share price is in focus after the company reported ...

Jan 29 (Reuters) - Medical device maker ResMed (RMD.N), opens new tab on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep ...

In its Q2 2026 earnings call, ResMed Inc. reported an earnings per share (EPS) of $2.81, surpassing analysts’ forecast of $2.73 by 2.93%. The company matched revenue expectations at $1.4 billion.